There was no difference in the primary end-point , median progression-free survival ( PFS ) for gemcitabine plus sorafenib versus gemcitabine plus placebo ( 3.0 versus 4.9 months , P = 0.859 ) , and no difference for median overall survival ( OS ) ( 8.4 versus 11.2 months , P = 0.775 ) .